Leiden Bio Science Park, Biopartner 2
J.H Oortweg 21 Leiden
(0) 71 332 2866
Follow us on Linkedin
11 April 2019
Leiden, The Netherlands, April 11, 2019 – VitroScan, developing tests to predict treatment outcome for cancer patients, has closed a round of seed funding for €800.000. Lead investor Libertatis Ergo Holding B.V. (LEH) will be welcomed as new board member. Pieter Geelen, TomTom founder and philanthropist, and co-founder of VitroScan also provides a major part of the funds in this round. VitroScan will use the proceeds to deliver Proof of Concept for application of its unique technology for treatment response prediction for cancer patients.
High failure rates of clinical trials with cancer drugs, suboptimal therapy responses for patients, and unnecessary side effects, cause a high burden on the health care system. This emphasizes the need for more efficient drug development, and better selection of treatment for the individual patient.
VitroScan’s unique technology platform combines automated 3D cell culture with high content 3D imaging and analysis in a robust platform that provides scalability without compromising precision of drug response analysis. A clinical trial program has been initiated with leading cancer hospitals in The Netherlands to establish the value of the technology for drug response prediction in selected cancers.
Quote LEH: “Leiden University is very excited to support VitroScan’s ambition to develop solutions and optimize treatment for cancer patients, to build on the strong technical foundation between VitroScan and Leiden University and to support entrepreneurship on the Leiden Bio Science Park.”
Quote Willemijn Vader, Managing Director VitroScan: “We are excited to welcome LEH in the board of VitroScan. LEH’s expertise will facilitate collaborations with the University Medical Centers, like LUMC and the Leiden Bio Science Park Community, and will be valuable to execute our strategy and achieve our goals.”
VitroScan B.V. is a Dutch biotech company based at the Leiden Bio Science Park. The company was founded in September 2016 as a spin-off company from OcellO, and has a license to the OcellO technology platform to develop predictive testing for oncology patients. VitroScan has established a solid network at the Leiden Bio Science Park and in the medical field including LUMC, Radboudumc, Erasmus MC, and regional hospitals to develop diagnostics in close collaboration with the end user.
VitroScan is dedicated to deliver products to personalize cancer therapy.
About Libertatis Ergo Holding B.V. (LEH):
LEH is a holding company of Leiden University with a goal to generate impact through valorization and technology investments coming from Leiden and in support of the development of the Leiden Bio Science Park.
About Pieter Geelen:
Pieter Geelen is one of the four original co-founders of navigation company TomTom. In 2006, he set up the Turing Foundation, a charity based in Amsterdam.
Back to overview
News & Events
VitroScan closes €800k seed funding round